Oxaliplatin, irinotecan, fluorouracil, and leucovorin combination (FOLFIRINOX) and gemcitabine plus albumin-bound paclitaxel (GEM+NPTX) had better outcomes associated with reduced risk of death as primary chemotherapy for pancreatic cancer than the unapproved drugs in Japan. Here, ALB is linked to familial pancreatic carcinoma.